Merck Completes Acquisition of Verona Pharma, Adding COPD Drug Ohtuvayre to Portfolio
I'm PortAI, I can summarize articles.
Merck has completed its acquisition of Verona Pharma, making it a wholly-owned subsidiary. As a result, Verona Pharma’s American Depositary Shares will no longer be traded on the Nasdaq. This acquisition adds Ohtuvayre, a new treatment for COPD, to Merck’s portfolio. Ohtuvayre is the first novel inhaled mechanism for COPD maintenance in over 20 years and has received FDA approval. Merck aims to expand access to this medication and collaborate with Verona Pharma's team to enhance its performance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments